Novartis AG
Compositions and methods for modulating farnesoid X receptors

Abstract:

The present invention relates to compounds of Formula I, ##STR00001## a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).